Candriam Equities L Life Care N Fonds
Anlageziel
The objective of the sub-fund is to benefit from the performance of the markets in equities of companies active in the pharmaceuticals, healthcare, medical technologies and biotechnology sectors, by investing in stocks of companies selected by the asset manager on the basis of their expected return, and to outperform the benchmark. This sub-fund invests primarily in equities, and/or securities equivalent to equities, of companies throughout the world which are active in the pharmaceuticals, healthcare, medical technologies and biotechnology sectors. It may also invest in companies with a high proportion of sales relating to the improvement of health conditions.
Stammdaten
| Name | Candriam Equities L Life Care N USD Acc Fonds |
| ISIN | LU2346220721 |
| WKN | A3C24U |
| Fondsgesellschaft | Candriam |
| Benchmark | MSCI World |
| Ausschüttungsart | Thesaurierend |
| Manager | Servaas Michielssens, Pierre Vaurice |
| Domizil | Luxembourg |
| Fondskategorie | Aktien |
| Auflagedatum | 31.01.2024 |
| Geschäftsjahr | 31.12. |
| VL-fähig? | Nein |
| Depotbank | CACEIS Bank, Luxembourg Branch |
| Zahlstelle | CACEIS Bank, Paris, succursale de Nyon / Suisse |
| Riester Fonds | Nein |
Basisdaten
| Auflagedatum | 31.01.2024 |
| Depotbank | CACEIS Bank, Luxembourg Branch |
| Zahlstelle | CACEIS Bank, Paris, succursale de Nyon / Suisse |
| Domizil | Luxembourg |
| Geschäftsjahr | 31.12. |
Aktuelle Daten
| Morningstar Rating | |
| Aktueller Rücknahmepreis | 156,30 |
| Anzahl Fonds der Kategorie | 817 |
| Volumen der Tranche | 47.994,05 USD |
| Fondsvolumen | 767,77 Mio. USD |
| Total Expense Ratio (TER) | 2,30 |
Gebühren
| Laufende Kosten | 2,48% |
| Total Expense Ratio (Verwaltungsgebühren & sonst. Kosten) | 2,30% |
| Transaktionskosten | 0,18% |
| Depotbankgebühr | - |
| Managementgebühr | 2,00% |
| Rücknahmegebühr | - |
| Ausgabeaufschlag | - |
Performancedaten
| Veränderung Vortag | 0,03 |
| WE seit Jahresbeginn | 7,83% |